CONFERENCE ON SELF-DESTRUCTING (SINGLE-USE) SYRINGES

自毁或一次性使用的核武器的发展和普遍采用， 针头和注射器可以防止随意重复使用和共享这些 装置. 开发用于预防血液传播的注射器 人类免疫缺陷病毒（HIV）和其他病原体的传播， 至少自1984年以来一直在提倡。 许多这样的装置已经被 专利，似乎是实用，有效和经济。 尽管如此，自毁注射器的生产和广泛使用， 没有发生。 一个“自毁（一次性）皮下注射器会议”是 提出的目标是评估概念和当前的设计， 促进进一步发展，并探讨 实施. 具体问题包括：（1） 自毁式注射器设计的艺术;（2） 自毁式注射器，以防止 注射药物滥用者;（3）其减少 在保健过程中无意中传播传染性微生物 （4）疫苗接种和疫苗接种之间的关系; 自毁式针头的发展以及 自动保护卫生工作者免受意外针刺伤害;以及（5） 社会法律和实际问题，可能会反对这样一个 “技术修复”造成的问题，重复使用的注射器之间， 合法和非法用户。 会议将在纽约市的纽约大学医学院举行 1991年4月18日至19日，中心1.5天。 共有150名注册者 预计观众将由学术界人士组成， 社区，包括那些从事药物滥用研究，医疗 工程学和流行病学;工商界，包括注射器 制造商和个人发明者;世界卫生组织;以及 联邦、州和地方政府，包括 国家药物滥用研究所，食品和药物管理局， 国家职业健康与安全研究所， 疾病控制，卫生部和地区检察官办公室。

The development and universal adoption of self-destructing, or single-use, needles and syringes could prevent the casual re-use and sharing of these devices. Development of such syringes for prevention of blood-borne transmission of human immunodeficiency virus (HIV) and other pathogens has been advocated since at least 1984. A number of such devices have been patented that appear to be practical, effective and economical. Nonetheless, production and widespread use of self-destructing syringes has not occurred. A "Conference on Self-destructing (Single-use) Hypodermic Syringes" is proposed with the goals of evaluating the concept and current designs, stimulating further development, and exploring impediments to implementation. Specific issues to be examined include (1) the state of the art of self-destructing syringe design; (2) potential effectiveness of self-destructing syringes for the prevention of needle-sharing among injected substance abusers; (3) their potential utility for reducing inadvertent spread of infectious organisms in the course of health care delivery and vaccination programs; (4) relationships between the development of self-destructing needles and the development of needles that automatically protect health workers from accidental needle sticks; and (5) socio-legal and pragmatic issues that might argue against such a "technological fix" to the problems posed by reused syringes among both licit and illicit users. The conference will be held in New York City on the campus of NYU Medical Center for 1.5 days around April 18-19, 1991. A total of 150 registrants is expected with the audience comprised of persons from the academic community, including those engaged in the study of substance abuse, medical engineering and epidemiology; the business community, including syringe manufacturers and individual inventors; the World Health Organization; and the federal, state and local governments, including persons from the National Institute on Drug Abuse, the Food and Drug Administration, the National Institute on Occupational Health and Safety, the Centers for Disease Control, departments of health and district attorneys offices.